Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $34.00

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its target price boosted by investment analysts at HC Wainwright from $28.00 to $34.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 129.89% from the stock’s current price.

AMLX has been the topic of a number of other reports. Bank of America boosted their price target on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Stifel Nicolaus started coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $21.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.56.

Amylyx Pharmaceuticals Price Performance

AMLX stock traded up $0.68 during mid-day trading on Wednesday, reaching $14.79. The company had a trading volume of 299,032 shares, compared to its average volume of 1,383,974. Amylyx Pharmaceuticals has a 52 week low of $3.00 and a 52 week high of $17.49. The stock has a 50 day simple moving average of $13.82 and a two-hundred day simple moving average of $13.15. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of -8.22 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. On average, equities analysts predict that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Justin B. Klee sold 1,995 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the transaction, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at $46,939,838.22. The trade was a 0.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joshua B. Cohen sold 136,193 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total value of $1,850,862.87. Following the completion of the transaction, the chief executive officer directly owned 3,378,621 shares of the company’s stock, valued at $45,915,459.39. This trade represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 151,203 shares of company stock worth $2,028,385. Company insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC boosted its holdings in Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after buying an additional 2,487,617 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Amylyx Pharmaceuticals by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after acquiring an additional 143,065 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $149,000. Acadian Asset Management LLC increased its stake in Amylyx Pharmaceuticals by 135.1% in the 2nd quarter. Acadian Asset Management LLC now owns 569,083 shares of the company’s stock valued at $3,645,000 after purchasing an additional 326,976 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new position in Amylyx Pharmaceuticals during the second quarter worth $113,000. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Key Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Quarterly earnings: AMLX reported GAAP EPS of ($0.30), beating consensus by $0.01 — management commentary on margin improvement and lowered losses helped sentiment. Press Release
• Positive Sentiment: Analyst upgrade/coverage: Stifel Nicolaus initiated coverage with a “Buy” rating and $21 price target (~49% upside vs recent levels), which likely supported the stock’s upward move by increasing buy-side interest. Benzinga
• Positive Sentiment: Valuation and pipeline story: Recent coverage highlighted Amylyx’s reduced losses and progress in its late‑stage pipeline, improving the company’s valuation narrative for investors focused on eventual commercialization or partner/licensing outcomes. A Look At Amylyx Pharmaceuticals Valuation
• Neutral Sentiment: Earnings call transcript available: The full Q4 2025 earnings call transcript provides detail on revenue cadence, R&D spend and trial timelines for investors who want to parse forward guidance and clinical milestones. Earnings Call Transcript
• Neutral Sentiment: Short interest data appears anomalous: Reports flagged a “significant increase” in March short interest but published values show zeros/NaN and days‑to‑cover of 0.0 — the data is unreliable as posted and should be confirmed before drawing conclusions about short pressure. (No external link provided)

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.